ArticleFrontiers in oncology2022

Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma.

Sebastiano Barco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.